Stay On Top of New Treatments for Alopecia Areata
October 2024
Baricitinib (Olumiant) and ritlecitinib (Litfulo) will be two new once-daily oral treatments for severe alopecia areata.
About 4% of adults and children develop alopecia areata...a condition where the immune system attacks hair follicles and causes patchy or complete hair loss on the scalp, face, or body.
Baricitinib and ritlecitinib inhibit Janus kinases (JAK), similar to tofacitinib (Xeljanz). Ritlecitinib also inhibits other kinases called TEC. Blocking kinases reduces inflammation and helps with hair regrowth.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive